Quest Diagnostics stock reports growth as reimbursement risk rises

Quest Diagnostics reported strong Q2 2026 revenue growth of 10.2% to $3.043 billion, and raised its full-year revenue outlook. Despite this growth, the stock experienced a slight decline in after-hours trading due to a narrower operating margin and the impending risk of up to 15% reimbursement cuts from the Centers for Medicare and Medicaid Services in 2027, posing a challenge for investors.